Embed
Email

quick

Document Sample

Shared by: ajizai
Categories
Tags
Stats
views:
0
posted:
12/20/2011
language:
pages:
26
Access to essential drugs:

staggering inequities - unparalleled opportunities









Jonathan D. Quick, MD, MPH

Director, Essential Drugs and Medicines Policy

Health Technology and Pharmaceuticals Cluster

World Health Organization

Presented at SEAM Conference, Washington, DC

27-29 November 2001

Access to essential drugs:

staggering inequities - unparalleled opportunities







Inequities







Opportunities









2 WHO SEAM Access.ppt (20-Dec-11)

Inequities



Economic inequity - percent of population below

the poverty line has changed little in 2 decades





Percent of population below poverty line (US $1 per day)



E. Europe & Central Asia

1993

Middle East & North Africa

1977

Latin America

East Asia

Sub-Saharan Africa

South Asia



0 10 20 30 40 50





3 WHO SEAM Access.ppt (20-Dec-11)

Source: WHO/HFA (1997)

Inequities



Health status inequity - infant mortality still

varies 10-fold among regions of the world





High Income Countries

E. Europe & Central Asia

Latin America

East Asia

Arab States

South Asia

Sub-Saharan Africa



0 20 40 60 80 100

Deaths per 1000 live births





4 WHO SEAM Access.ppt (20-Dec-11)

Source: WHO/HFA (1997)

Inequities



R&D inequity - expenditures grow, new drugs

are launched, few specific for tropical diseases



Between 1975 and 1997 -

R&D expenditure

New chemical entities  1,223 new compounds launched (US$ billions -

launched (number)  only 11 for tropical diseases top companies)

65 40



60 35



30

55

25

50

20

45

15

40

10

35 5



30 0

1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997







Sources: D. Gannaway and PriceWaterhouseCoopers (1999)

5 WHO SEAM Access.ppt (20-Dec-11)

R&D, NCE data; P. Trouiller et al (1999) tropical research data

Therapeutic inequity - growing resistance is

affecting prevalent infectious diseases



 Malaria

 chloroquine resistance in 81/92 countries

 Tuberculosis

 2 - 40 % primary multi-drug resistance

 Gonorrhoea

 5 - 98 % penicillin resistance in N. gonorrhoeae

 Pneumonia and bacterial meningitis

 12 - 55 % penicillin resistance in S. pneumoniae

 Diarrhoea: shigellosis

 10-90+ % amp, 5-95% TMP/SMZ resistance







6 WHO SEAM Access.ppt (20-Dec-11)

Source: DAP, EMC, GTB, CHD (1997)

Inequities



Health literacy inequity - information explosion

for some people, information poverty for others



 Among high income countries -

 300+ million world-wide internet users by 2000

 2/3 of users search for health information

 43% of 700,000 US doctors or their staff browse the Web

 67% of doctor’s patients have Internet information

 Among low and middle income countries -

 available information often under-utilized

 1/2 of drugs with sufficient information for safe, effective use

 only 1/4 of drug packets in Asia contain inserts

 25-45% of adult women illiterate - over 90% in some countries





Source: D. Gannaway (1999), World Development

7 WHO SEAM Access.ppt (20-Dec-11)

Report (1997), WHO/DAP (1998), WHO/EDM (1999)

Inequities



Pharmaceutical care inequity - a 100-fold

variation in pharmacists per million population

Italy

Canada

United Kingdom

Denmark

Thailand Europe, N. America

Sri Lanka Asia (150 to 940 per million)

Philippines (10 to 70 per million)

Myanmar

Bhutan

Swaziland Pharmacists per one million population

Benin

Malawi

Africa

Ethiopia (1 to 30 per million)

Central African Republic





0 200 400 600 800 1000



8 WHO SEAM Access.ppt (20-Dec-11)

Source: WHO/HST/GSP/94.1 (1994)

Inequities



Affordability inequity - number of working

hours to pay full treatment course

Hours

600

500

500 460



400

Tuberculosis

300

Shigellosis

200 120 Gonorrhoea

100 20 20 6 1.4 1.4 0.4

0

Tanzania Thailand Switzerland



Based on average worldwide price and national

per capita income. Source: WHO/EDM

9 WHO SEAM Access.ppt (20-Dec-11)

Inequities



Financing inequity - the burden falls heaviest on

those least able to pay

Drugs are the largest health expenditure for poor households



Azerbaijan Bangladesh Mali

Drugs

61% Drugs Drugs

73% 80%



Inequity in health and pharmaceutical financing:

High income countries: 50-90 % publicly funded

Low/middle income countries: 50-90 % out-of-pocket

Fees,

Fees, Other

Other 20%

Fees,

Other 27%

39%





Source: Azerbaijan - UNICEF-Bamako Technical Report No. 35 ; Bangladesh 1995 - National Accounts 1996/97

Mali (1986) - Diarra K and Coulibaly S. Financing of recurrent health costs in Mali. Health Policy and planning; 1990, 5(2);126-138



10 WHO SEAM Access.ppt (20-Dec-11)

Inequities





Access inequity - financing, delivery, and other

constraints still limit access to essential drugs

Percentage of population with regular access to essential drugs

(1997)

1/3 of world’s population

lacks regular access

320 million in Africa

have 95% (41)

5 = No data available (1)







11 WHO SEAM Access.ppt (20-Dec-11)

Source: WHO/DAP (1998)

Inequities



People are needlessly suffering and dying - drugs

unavailable, unaffordable, unsafe, or wrongly used

AIDS

14%



Acute In Africa and S.E.Asia:

Other causes respiratory

35%

 1/2 of deaths among children,

infections young adults due to 6 diseases

11%

 prompt diagnosis and

treatment could save over

Diarrhoeal 3 million lives per year

diseases

11%

Malaria

Maternal & 8%

perinatal TB

2% Measles

conditions

6%

13%



12 WHO SEAM Access.ppt (20-Dec-11)

Access to essential drugs:

staggering inequities - unparalleled opportunities







Inequities







Opportunities









13 WHO SEAM Access.ppt (20-Dec-11)

Ensuring access to essential drugs

- framework for collective action

3. Sustainable

1. Rational financing

3. Sustainable

selection and use financing

1. Rational

selection









ACCESS

ACCESS









health and

4. Reliable





systems

supply

4. Reliable

2. Affordable

health and

prices

2. Affordable supply systems



prices

14 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Essential drugs concept nearly universal - lists

and guidelines put the concept into practice









158 countries with

essential drugs lists

90 countries with

treatment guidelines

83 countries with both Essential drugs lists (only) (75)

Treatment guidelines (only) (7)

Essential drug list & guidelines (83)





15 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Standard treatment guidelines (STGs) -

save lives when effectively implemented

STG, training, mass education



STG & training



STG, training, mass education



STG, supervision, training



STG, mass education, print materials



Supervision, training



Supervision, training



Supervision, training





0% 10% 20% 30% 40% 50% 60%

% reduction in acute respiratory infection (ARI) mortality

among children age 5 and under





Source: WHO/CDS/CSR/DRS/2001.9

16 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Getting mothers and clinicians to talk

- reducing injection use in Indonesia

100% Interactive group discussion

Proportion of visits









Seminar (both groups)

with injection







80%



60% District-wide monitoring

(both groups)

40%



20%



0%

1 3 5 7 9 11 13 15 17 19 21 23 25

Months

Comparison group Interactive group discussion





Source: Long-term impact of small group interventions, Santoso et al.,

1996

17 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Advocacy, corporate responsiveness, &

competition have reduced prices 95% in 3 years



Indicative annual cost per person for triple therapy in

Africa (US $)

$10,000



$8,000

UN Drug Access Initiative



$6,000



$4,000 Domestic production





$2,000 Accelerated access initiative

??

Generic offers

$0

1996 1997 1998 1999 2000 2001 2002





18 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Competition is highly effective in reducing

prices - the example of antiretrovirals



Cost per capsule or tablet (US $)

No competition Competition (2 to 6 producers per product)

5

4

2.90

3

2.00 1.85

2 1.72 1.55

1.31

1.04

1 0.83

0.51

0.08

0

Product A Product B Product C Product D Product E

1996 1997 1998 1999 2000



Source = UNAIDS, B. Samb, 2000







19 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Drug benefits in public health insurance -

access and risk-sharing









Drugs covered by public health insurance (71)



20 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Global Fund to fight AIDS, Tuberculosis and

Malaria - pledges from May to August 2001

?

1,600 $ 1.5 billion

1,400

1,200

US $ millions

1,000

800

600

400

200

0

3- 10- 17- 24- 31- 7- 14- 21- 28- 5- 12- 19- 26- 2-

May May May May May Jun Jun Jun Jun Jul Jul Jul Jul Aug









21 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Shopkeeper training - helping households get

the best value for their health spending

% of surrogate shoppers

70%

60%

Training Training

50%

40%

30%

20%

10%

0%

1998 1999 2000 1998 1999 2000





Southern zone Northern zone



Fevers treated with antimalarials Antimalarials given appropriately







Source: Marsh et al, 2001



22 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems



Reliable health and supply systems

- successful examples exist in all regions









Direct delivery system - privatized, decentralized

Primary distributor system - privatized, centralized

Autonomous medical stores - partly private, centralized





23 WHO SEAM Access.ppt (20-Dec-11)

 Selection  Affordability  Financing  Health systems





India - state essential drugs programmes

developed through an NGO

Himachal Pradesh

Punjab

Components

Haryana

 State drug policy Delhi State

 Essential drugs lists by level of care Rajasthan

 Pooled procurement Bihar

 Efficient distribution Madhya Pradesh

Gujarat

 Quality assurance West Bengal

 Information--patients & prescribers Maharashtra

 Training in rational prescribing

 Studies on drug use, pharmacoeconomics Andhra Pradesh

Goa



13 states - total population

580 million Tamil Nadu





24 WHO SEAM Access.ppt (20-Dec-11)

Conclusion





Staggering inequities exist - in income,

health status, R&D, pharmaceutical care, and access



Unparalleled opportunities exist - to build

on local successes to expand access for those in need





1. Rational 3. Sustainable

selection & use financing



ACCESS

4. Reliable

2. Affordable

health

prices

systems



25 WHO SEAM Access.ppt (20-Dec-11)



Related docs
Other docs by ajizai
NH_Members
Views: 0  |  Downloads: 0
06 Mr. Wu Jun 16012009
Views: 0  |  Downloads: 0
9i CITY OF RAPID CITY
Views: 0  |  Downloads: 0
K Readiness Doc. July 2010
Views: 0  |  Downloads: 0
LookMaNoHands
Views: 0  |  Downloads: 0
97605964
Views: 0  |  Downloads: 0
NBA 2006-07 data
Views: 0  |  Downloads: 0
By registering with docstoc.com you agree to our
privacy policy

You are almost ready to download!

You are almost ready to download!